Should I have PSA screening?
Discuss age, family history, ancestry, health and preferences with your doctor.
PSA-first screening guide
Blood Test for Prostate Cancer: PSA First, Galleri Is Not Built for It
The right test comes first: what PSA shows, why screening is a shared decision, and why Galleri is not a prostate-screening substitute.
Start with the direct answerHLI editorial team
Evidence checked by the editorial team. A urologist and genetic counselor have not yet been supplied; no medical reviewer is represented in the page schema.
The answer first
The standard blood test for prostate cancer is the PSA test, ordered with your doctor after a shared decision. The USPSTF gives PSA screening a Grade C for men ages 55–69. Galleri® is not designed to screen for prostate cancer: prostate is outside its pre-specified 12, and it detected 11.2% of prostate cancers in a published case-control analysis. A “No Cancer Signal Detected” result says little about your prostate.
This page is educational and cannot interpret an individual PSA or replace care from a clinician.
Begin with the established test
Which Blood Test Screens for Prostate Cancer?
PSA (prostate-specific antigen) is the blood test used to screen for prostate cancer. It measures a protein made by normal and cancerous prostate cells. Screening is a shared decision because PSA can lead to useful early detection, false alarms and detection of cancers that would never cause harm. Galleri is not a substitute.
Refine the risk
A repeat PSA, examination, prostate-specific blood tests or MRI may come before biopsy.
Do not use Galleri instead
A negative Galleri result cannot reassure you about prostate cancer.
A number interpreted in context
How PSA Screening Works
A PSA test reports prostate-specific antigen in nanograms per milliliter (ng/mL). A value above 4 ng/mL is often treated as elevated, but no single threshold separates cancer from benign causes. Age, prostate size, medications and recent activity can all affect the result.
Clinicians may consider age-adjusted ranges, the ratio of free to total PSA, change over time (PSA velocity) and PSA relative to prostate volume (PSA density). These measures inform risk; none diagnoses cancer by itself.
A digital rectal exam may add clinical context. If concern remains, prostate MRI can help identify an area for targeted biopsy. Pathology from biopsy—not the PSA number—establishes whether cancer is present and its Grade Group.
The central trade-off
PSA's Limits: False Alarms and Overdiagnosis
PSA can rise without cancer and can find slow-growing cancers that would never have caused harm. Benign prostate enlargement, prostatitis, recent ejaculation and cycling can raise PSA. An abnormal result can lead to repeat testing, anxiety, MRI or an unnecessary biopsy.
Overdiagnosis means finding a cancer that would not have affected a person's health. Some Grade Group 1 (Gleason 6) cancers are managed with active surveillance rather than immediate treatment, helping reduce treatment harms.
The USPSTF's 2018 recommendation makes PSA screening an individual decision for men ages 55–69 (Grade C) and recommends against screening from age 70 (Grade D). That shared-decision frame is a response to both possible benefit and possible harm.
After PSA raises a question
Other Prostate-Specific Blood Tests: 4Kscore, PHI, IsoPSA
These tests can refine the chance of clinically significant prostate cancer before biopsy. They are not multi-cancer screens and do not replace clinical interpretation.
Four kallikrein markers
Combines four prostate-related blood biomarkers with clinical information to estimate risk and inform next steps after a concerning PSA.
Three forms of PSA
The Prostate Health Index combines total PSA, free PSA and [-2]proPSA to refine risk.
PSA structure
Assesses structural differences in PSA. Regulatory status and local availability should be confirmed with a clinician before relying on it.
Urine tests such as PCA3 and SelectMDx may also be used selectively after an abnormal evaluation. Test choice depends on clinical context and local availability.
The data do not support substitution
What Galleri Does, and Does Not, Do for Prostate Cancer
Galleri looks for cancer-associated DNA methylation patterns in blood. It is not designed to screen for prostate cancer, and prostate is not one of GRAIL's pre-specified group of 12 cancers.
11.2%Overall prostate sensitivity: 47 of 420 in the Mahal et al. case-control analysis
31.9%Grade Group 4–5 detection: 36 of 113, meaning about two in three were missed
99.5%Specificity in the cited CCGA case-control analysis; not a prostate-screening endorsement
The same analysis reported stage sensitivity of 3.2% at Stage I, 4.7% at Stage II, 14.9% at Stage III and 81.5% at Stage IV. Most detected cases were higher grade or later stage because larger, more advanced tumors shed a stronger signal. That pattern is not evidence that Galleri is a good prostate screening test.
Galleri missed about 89% of prostate cancers overall and about 68% of the highest-grade cancers in that dataset. Its methylated-fraction correlation with PSA was weak (r=0.42), reflecting different measurements. A positive result assigned to the prostate requires urologic diagnostic workup; it is not a diagnosis.
GRAIL's “50+ cancer types” list describes cancers study participants had when a signal was detected; it is not a per-cancer performance claim. The pre-specified 12 are anus, bladder, colorectal, esophagus, head and neck, liver/bile duct, lung, lymphoma, myeloma/plasma cell neoplasm, ovary, pancreas and stomach. Read the broader cancers evidence overview.
Different questions, not competing products
PSA and Galleri Side by Side
PSA asks whether the prostate is making an unusual amount of a prostate protein. Galleri asks whether a multi-cancer methylation signal is present—and it is not built for the prostate.
| Question | PSA | 4Kscore | PHI | IsoPSA | Galleri |
|---|---|---|---|---|---|
| What it measures | PSA protein in blood (ng/mL) | Four prostate-related kallikrein biomarkers | Three forms of PSA | Structural differences in PSA | Cancer-associated cfDNA methylation patterns |
| Usual role | First-line screening discussion and prostate evaluation | Refines risk after an abnormal or concerning PSA | Refines risk after an abnormal or concerning PSA | Refines risk before deciding on further workup | Multi-cancer screening; not designed for prostate cancer |
| Prostate-specific? | Yes | Yes | Yes | Yes | No |
| Meaning of a negative result | Does not rule cancer out | May inform next steps; does not rule cancer out | May inform next steps; does not rule cancer out | May inform next steps; does not rule cancer out | Says little about the prostate; about 89% were missed in the cited analysis |
| Guideline position | USPSTF: shared decision ages 55–69; recommends against screening at 70+ | Used selectively in clinical risk assessment | Used selectively in clinical risk assessment | Use and availability depend on clinical context | No USPSTF, ACS or NCCN prostate-screening endorsement |
Not a head-to-head performance comparison. No single PSA sensitivity or specificity figure is presented because results vary by cutoff, population and cancer definition. The Galleri prostate figures come from a case-control analysis and do not establish population-screening performance.
Predisposition is not detection
Inherited Prostate Cancer Risk: BRCA2, HOXB13, ATM
Prostate cancer is highly heritable: NCI reports that inherited factors may account for up to 60% of risk, mostly through many common small-effect variants. A minority of men carry rarer variants in genes such as BRCA2, HOXB13 or ATM that can confer higher risk. Genetic testing does not detect an existing cancer and does not replace PSA.
BRCA2
NCI PDQ reports a pooled relative risk of 6.08 for aggressive prostate cancer. BRCA2 is also relevant to inherited breast, ovarian and pancreatic cancer risk.
HOXB13
The G84E variant is associated with higher risk and is found mainly in people of European ancestry. The X285K variant has been linked to higher risk in men of West African ancestry. Ancestry affects which findings are informative.
ATM and other genes
ATM has been associated with higher risk, but evidence is less settled. NCCN-guided germline panels may include several prostate-risk and DNA-repair genes for people who meet clinical criteria.
Confirm the right genetic test first
Men with a father, brother or several relatives affected by prostate, breast, ovarian or pancreatic cancer—and some men with Ashkenazi Jewish ancestry—can ask about genetic education and counseling. A clinician-ordered germline panel may be the better route for someone who meets NCCN criteria. HLI's current whole-genome report scope has not been confirmed for BRCA1, BRCA2, HOXB13 or ATM, so this page does not claim coverage. Read about BRCA1 and BRCA2 and what a result means, or see what the $599 genome service includes.
Make the decision with a clinician
Who Should Be Screened?
The USPSTF recommends shared decision-making about PSA screening for men ages 55–69 and recommends against PSA screening at age 70 or older. The American Cancer Society suggests beginning the conversation at 50 for average-risk men and at 40–45 for higher-risk men, including Black men and those with a close relative diagnosed young.
- Family history and known inherited variants can justify an earlier, more individualized conversation.
- NCI PDQ reports that Black men have about 67% higher prostate cancer incidence and more than twice the prostate-cancer death rate of White men; access, environment and care inequities also shape outcomes.
- Symptoms such as trouble urinating, blood in urine or semen, persistent bone pain or unexplained weight loss need diagnostic evaluation, not screening alone.
- Galleri is recommended by its maker for adults with elevated cancer risk, such as those 50 or older, but it is not a prostate-screening test and does not replace this conversation.
Clear answers
FAQ
Is PSA the only blood test for prostate cancer?
No. The 4Kscore, Prostate Health Index (PHI) and IsoPSA can help refine risk after a PSA result. They all evaluate prostate-related proteins. Galleri is a multi-cancer test and is not designed to screen for prostate cancer.
Can Galleri screen for prostate cancer?
Not reliably. In a published case-control analysis, Galleri detected 11.2% of prostate cancers and 31.9% of Grade Group 4–5 cancers. Prostate is outside GRAIL’s pre-specified group of 12 cancers.
Does a “No Cancer Signal Detected” Galleri result mean my prostate is fine?
No. Galleri missed about 89% of prostate cancers in that analysis. Follow the PSA screening decision you make with your doctor, and seek care for symptoms or concerns.
Does Galleri replace PSA?
No. Galleri does not replace PSA or the shared-decision conversation about prostate screening.
Is prostate cancer inherited?
Inherited factors contribute substantially to prostate cancer risk, mostly through many common variants. A minority of people carry rare higher-risk variants such as harmful changes in BRCA2 or HOXB13.
Can whole genome sequencing tell me if I have prostate cancer?
No. Whole genome sequencing does not detect an existing prostate cancer and does not replace PSA. Genetic testing can inform inherited risk; the appropriate test and its gene coverage should be reviewed with a doctor or genetic counselor.
Sources and Evidence Notes
Claims were drawn from government guidance, peer-reviewed studies and primary company materials identified in the supplied content brief. Study results describe populations, not an individual outcome. Regulatory status should be rechecked before publication.
- NCI PDQ — Genetics of Prostate Cancer
- NCI — BRCA Gene Changes: Cancer Risk and Genetic Testing
- Mahal et al., JCO Precision Oncology (2024), PMID 39208374; a published erratum exists.
- Klein et al., Annals of Oncology (2021), CCGA3
- GRAIL — NHS-Galleri full-results release, May 30, 2026; source for the pre-specified 12 cancers.
- GRAIL — PATHFINDER 2 full results, ASCO, May 31, 2026.
- USPSTF — Prostate Cancer Screening (2018)
- American Cancer Society — Prostate Cancer Early Detection Recommendations
- NCCN — Prostate Cancer Early Detection guideline.
- NCCN — Genetic/Familial High-Risk Assessment guideline.
- Prostate Cancer UK — Galleri and prostate cancer evidence review
- FDA — September 2026 advisory committee materials